Treatment results of all CoALL 07-03 patients according to presenting features
| Factor . | n . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| pEFS . | Survival . | ||||||||||
| Year 5 . | Year 10 . | . | Year 5 . | Year 10 . | |||||||
| Prob. . | SE . | Prob. . | SE . | P . | Prob. . | SE . | Prob. . | SE . | P . | ||
| Immunophenotype | |||||||||||
| Non-T NCI standard | 474 | 87.9 | 1.5 | 87.1 | 1.6 | .000 | 95.8 | 0.9 | 94.9 | 1.0 | .000 |
| Non-T NCI high | 189 | 77.2 | 3.1 | 75.9 | 3.1 | 86.2 | 2.5 | 83.7 | 2.8 | ||
| T-ALL NCI standard | 32 | 78.1 | 7.3 | 78.1 | 7.3 | .650 | 87.4 | 5.9 | 83.6 | 6.8 | .990 |
| T-ALL NCI high | 78 | 81.9 | 4.4 | 81.9 | 4.4 | 85.8 | 4.0 | 84.4 | 4.1 | ||
| Non-T | 663 | 84.8 | 1.4 | 83.9 | 1.4 | .260 | 93.0 | 1.0 | 91.7 | 1.1 | .007 |
| T-ALL | 110 | 80.8 | 3.8 | 80.8 | 3.8 | 86.2 | 3.3 | 84.1 | 3.5 | ||
| Sex | |||||||||||
| Male | 429 | 82.4 | 1.8 | 81.7 | 1.9 | .100 | 91.6 | 1.3 | 89.7 | 1.5 | .290 |
| Female | 344 | 86.6 | 1.8 | 85.7 | 1.9 | 92.7 | 1.4 | 91.9 | 1.5 | ||
| Age at diagnosis | |||||||||||
| Age <10 y | 601 | 85.6 | 1.4 | 85.0 | 1.5 | .021 | 93.8 | 1.0 | 92.7 | 1.1 | .000 |
| Age ≥10 y | 172 | 79.5 | 3.1 | 78.0 | 3.2 | 85.9 | 2.7 | 83.2 | 3.1 | ||
| WBC, × 109/L | |||||||||||
| WBC <25 | 525 | 86.0 | 1.5 | 84.3 | 1.6 | .080 | 94.6 | 1.0 | 92.9 | 1.1 | .002 |
| WBC ≥25 | 248 | 80.6 | 2.5 | 80.0 | 2.6 | 86.7 | 2.2 | 86.2 | 2.2 | ||
| CNS status | |||||||||||
| CNS negative | 743 | 85.1 | 1.3 | 84.3 | 1.4 | .001 | 93.1 | 0.9 | 91.8 | 1.0 | .000 |
| CNS positive | 20 | 60.0 | 11.0 | 60.0 | 11.0 | 64.6 | 10.8 | 59.2 | 11.1 | ||
| t(12;21) | |||||||||||
| ETV6-RUNX1 negative | 517 | 80.0 | 1.8 | 78.8 | 1.8 | .000 | 89.7 | 1.3 | 87.8 | 1.5 | .000 |
| Positive | 170 | 92.4 | 2.0 | 92.4 | 2.0 | 98.2 | 1.0 | 97.6 | 1.2 | ||
| Factor . | n . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| pEFS . | Survival . | ||||||||||
| Year 5 . | Year 10 . | . | Year 5 . | Year 10 . | |||||||
| Prob. . | SE . | Prob. . | SE . | P . | Prob. . | SE . | Prob. . | SE . | P . | ||
| Immunophenotype | |||||||||||
| Non-T NCI standard | 474 | 87.9 | 1.5 | 87.1 | 1.6 | .000 | 95.8 | 0.9 | 94.9 | 1.0 | .000 |
| Non-T NCI high | 189 | 77.2 | 3.1 | 75.9 | 3.1 | 86.2 | 2.5 | 83.7 | 2.8 | ||
| T-ALL NCI standard | 32 | 78.1 | 7.3 | 78.1 | 7.3 | .650 | 87.4 | 5.9 | 83.6 | 6.8 | .990 |
| T-ALL NCI high | 78 | 81.9 | 4.4 | 81.9 | 4.4 | 85.8 | 4.0 | 84.4 | 4.1 | ||
| Non-T | 663 | 84.8 | 1.4 | 83.9 | 1.4 | .260 | 93.0 | 1.0 | 91.7 | 1.1 | .007 |
| T-ALL | 110 | 80.8 | 3.8 | 80.8 | 3.8 | 86.2 | 3.3 | 84.1 | 3.5 | ||
| Sex | |||||||||||
| Male | 429 | 82.4 | 1.8 | 81.7 | 1.9 | .100 | 91.6 | 1.3 | 89.7 | 1.5 | .290 |
| Female | 344 | 86.6 | 1.8 | 85.7 | 1.9 | 92.7 | 1.4 | 91.9 | 1.5 | ||
| Age at diagnosis | |||||||||||
| Age <10 y | 601 | 85.6 | 1.4 | 85.0 | 1.5 | .021 | 93.8 | 1.0 | 92.7 | 1.1 | .000 |
| Age ≥10 y | 172 | 79.5 | 3.1 | 78.0 | 3.2 | 85.9 | 2.7 | 83.2 | 3.1 | ||
| WBC, × 109/L | |||||||||||
| WBC <25 | 525 | 86.0 | 1.5 | 84.3 | 1.6 | .080 | 94.6 | 1.0 | 92.9 | 1.1 | .002 |
| WBC ≥25 | 248 | 80.6 | 2.5 | 80.0 | 2.6 | 86.7 | 2.2 | 86.2 | 2.2 | ||
| CNS status | |||||||||||
| CNS negative | 743 | 85.1 | 1.3 | 84.3 | 1.4 | .001 | 93.1 | 0.9 | 91.8 | 1.0 | .000 |
| CNS positive | 20 | 60.0 | 11.0 | 60.0 | 11.0 | 64.6 | 10.8 | 59.2 | 11.1 | ||
| t(12;21) | |||||||||||
| ETV6-RUNX1 negative | 517 | 80.0 | 1.8 | 78.8 | 1.8 | .000 | 89.7 | 1.3 | 87.8 | 1.5 | .000 |
| Positive | 170 | 92.4 | 2.0 | 92.4 | 2.0 | 98.2 | 1.0 | 97.6 | 1.2 | ||
NCI, National Cancer Institute; Prob., probability.